PTC Therapeutics
PTCT
180 hedge funds and large institutions have $2.84B invested in PTC Therapeutics in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 56 increasing their positions, 74 reducing their positions, and 21 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
11% more call options, than puts
Call options by funds: $9.26M | Put options by funds: $8.38M
5% more capital invested
Capital invested by funds: $2.71B → $2.84B (+$136M)
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
0.51% less ownership
Funds ownership: 104.39% → 103.89% (-0.51%)
2% less funds holding
Funds holding: 183 → 180 (-3)
24% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$24.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.5M |
| 3 |
Goldman Sachs
New York
|
+$9.39M |
| 4 |
AC
Armistice Capital
New York
|
+$9.12M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$39.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$19.2M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$14.4M |
| 4 |
BlackRock
New York
|
-$9.57M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$6.7M |
PTCT Hedge Fund Activity: Q2 2022 in Review
180 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2022, worth a combined $2.84B — up 5% from $2.71B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new PTCT positions and 21 closed out — a net gain of 1 holder — while 56 added to existing stakes and 74 trimmed.
The largest buyer was Camber Capital Management, adding an estimated $24.5M. The largest seller was Wellington Management Group, cutting an estimated $39.2M.
- 180 institutional investors held PTC Therapeutics (PTCT) as of Q2 2022, down from 183 in Q1 2022.
- Funds reported $2.84B of PTC Therapeutics stock for Q2 2022, up 5% quarter-over-quarter.
- 22 funds opened new PTC Therapeutics positions in Q2 2022 and 21 closed out, a net change of +1 holder.
- The largest PTC Therapeutics buyer in Q2 2022 was Camber Capital Management, an estimated $24.5M added.
- The largest PTC Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $39.2M sold.
Based on aggregated 13F filings for Q2 2022.